Hillsdale Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Hillsdale Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.08M	Buy	639,100 +80,000	+14%	+$621K	0.17%	145
2025 Q4	$4.36M	Sell	559,100 -2,500	-0.4%	-$18.1K	0.12%	232
2025 Q3	$4.26M	Buy	561,600 +25,600	+5%	+$213K	0.13%	230
2025 Q2	$4.8M	Buy	536,000 +13,700	+3%	+$128K	0.18%	176
2025 Q1	$3.92M	Sell	522,300 -19,800	-4%	-$160K	0.2%	117
2024 Q4	$4.08M	Buy	542,100 +541,270	+65,213%	+$4.11M	0.21%	129
2024 Q3	$6.31K	Buy	+830	New	+$6.31K	﹤0.01%	561
2020 Q3	–	Sell	-172,000	Closed	-$820K	–	579
2020 Q2	$820K	Buy	+172,000	New	+$687K	0.07%	206

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Hillsdale Investment Management's BCRX Position: Q1 2026 in Review

Hillsdale Investment Management increased its BioCryst Pharmaceuticals (BCRX) stake by 14% in Q1 2026, buying an estimated $621K and bringing the position to 639,100 shares worth $6.08M. The position accounts for 0.17% of the portfolio, ranked #145.

Hillsdale Investment Management first reported a position in BCRX in Q2 2020 and has held it in 8 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Hillsdale Investment Management held 639,100 shares of BioCryst Pharmaceuticals worth $6.08M as of Q1 2026.
Hillsdale Investment Management bought 80,000 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $621K.
BioCryst Pharmaceuticals made up 0.17% of Hillsdale Investment Management's portfolio in Q1 2026, its #145 holding.
Hillsdale Investment Management first reported a position in BioCryst Pharmaceuticals in Q2 2020 and has held it in 8 quarters since.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.